Quantcast
Last updated on April 19, 2014 at 5:20 EDT

Latest diabetic neuropathy Stories

2009-09-17 10:40:00

DEL MAR, Calif., Sept. 17 /PRNewswire/ -- In a new online survey, eighty-five percent of people who experience diabetic nerve pain said that their pain was one of the top three most bothersome complications of their diabetes. Despite the fact that people with diabetic nerve pain recognize the condition's impact on their lives and eighty-four percent of those surveyed said they have discussed the condition with a healthcare provider, just slightly less than half of respondents (49...

2009-07-31 01:25:00

TOKYO, July 31 /PRNewswire/ -- R-Tech Ueno, Ltd. announced on July 29 after discussing its R&D policy at a meeting of the board of directors held on the day and determined the R&D items as follows. The company intends to actively strengthen R&D in the ophthalmologic & dermatological fields that are its priority and exclusive areas, and promote relevant affiliation, etc. with external entities. 1. Development code UF-021 (eye diseases) The item in question is isopropyl...

2009-07-22 07:09:00

DOYLESTOWN, Pa., July 22 /PRNewswire-FirstCall/ -- Quigley Pharma Inc., a wholly-owned subsidiary of The Quigley Corporation (Nasdaq: QGLY) www.quigleyco.com, today announced the results from its Phase IIb double-blind, placebo-controlled, study of topical compound QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. The study was completed with fewer than expected evaluable patients with the final and comprehensive conclusions revealing that (i) the compound is safe and...

2009-07-21 14:55:00

In the July issue of Biomaterials, published by Elsevier, researchers from the University of Central Florida (UCF) report on the first lab-grown motor nerves that are insulated and organized just like they are in the human body. The model system will drastically improve understanding of the causes of myelin-related conditions, such as diabetic neuropathy and later, possibly multiple sclerosis (MS). In addition, the model system will enable the discovery and testing of new drug therapies for...

2009-06-23 10:43:53

Multiple sclerosis, diabetic neuropathy, and other conditions caused by a loss of myelin insulation around nerves can be debilitating and even deadly, but adequate treatments do not yet exist. That's in large part because of deficiencies in model research systems. In an upcoming issue of the journal Biomaterials, a UCF team addresses this problem with a report on the first lab-grown motor nerves that are insulated and organized the same way they are in the body. The group's model system,...

2009-06-21 06:33:55

Specially designed virus-derived vectors "“ engineered not to cause disease "“ can take therapeutic genes to the malfunctioning peripheral neurons outside the spinal cord and brain, alleviating the pain and other dysfunction that can result from a chronic disease or drug treatment, said researchers from Baylor College of Medicine and the University of Glasgow in a report in the current issue of the Journal of Clinical Investigation. "These disorders that affect the dorsal root...

2009-06-10 10:56:57

 New research from Jefferson Hospital for Neuroscience (JHN) may redefine how Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is diagnosed. Eduardo De Sousa, M.D., assistant professor of Neurology at Jefferson Medical College of Thomas Jefferson University, and director of the Electrodiagnostic Neuromuscular Lab at JHN, led the study which looked at the number of demyelinating features that are needed to differentiate between CIDP, Amyotrophic lateral sclerosis (ALS, or Lou...

2009-06-08 06:00:00

Analysis of Subjects with Moderately Severe Diabetic Neuropathy Shows Statistically Significant Improvement in Multiple Quantitative Neurological Endpoints RICHMOND, Calif., June 8 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of as yet unreleased positive Phase 2 clinical data from its ZFP Therapeutic(TM) program to develop SB-509 as a treatment for diabetic neuropathy (DN) at the 69th Annual Scientific Sessions of the American Diabetes...

2009-05-21 07:00:00

Approved for peripheral neuropathic pain in non-diabetic adults SAN MATEO, Calif., May 21 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that the European Commission has formally granted marketing authorization of Qutenza(TM) 179 mg cutaneous patch (formerly NGX-4010) for the treatment of peripheral neuropathic pain in non-diabetic adults either alone or in...

2009-05-20 17:32:16

Monitoring blood fat levels as closely as blood sugar may help stem diabetic neuropathy, U.S. researchers suggest. Researchers at the University of Michigan and Wayne State University in Michigan analyzed data from 427 diabetes patients with neuropathy -- tingling, numbness, burning and pain -- and found those with higher blood triglycerides were more likely to develop a worsening of nerve loss symptoms within the year. These results set the stage for clinicians to be able to address...